CD8A and ovarian cancer: The FR-derived peptide vaccines E39 (FR-α 191−199) and E41 (FR-α 245−253) are efficiently presented to CD8+ T-cells and have showed potent anticancer effects in ovarian-cancer animals and good safety but weak immune response in ovarian cancer patients in a phase II clinical trial (Chianese-Bullock et al., 2008).